REQUEST A DEMO
Total
USD $0.00
View basket Checkout now
Search more companies

Aranyag-Pharma Bt. (Hungary)

Main Activities: Pharmacies and Drug Stores
Full name: Aranyag-Pharma Gyogyszerkereskedelmi es Szolgaltato Bt. Profile Updated: October 31, 2023
Buy our report for this company USD 29.95 Most recent financial data: 2022 Available in: English & Hungarian Download a sample report

Aranyag-Pharma Bt. is an enterprise located in Hungary, with the main office in Gyal. It operates in the Pharmacies and Drug Stores industry. Aranyag-Pharma Bt. was incorporated on May 06, 1999. It currently has a total number of 5 (2023) employees. In 2022, the company reported a net sales revenue drop of 14%. Its’ total assets recorded a growth of 52.79%. Aranyag-Pharma Bt.’s net profit margin decreased by 5.81% in 2022.

Headquarters
Korosi utca 36.
Gyal; Pest; Postal Code: 2360

Contact Details: Purchase the Aranyag-Pharma Bt. report to view the information.

Website: http://www.aranyaggyal.novodata.hu

Basic Information
Total Employees:
Purchase the Aranyag-Pharma Bt. report to view the information.
Outstanding Shares:
Purchase the Aranyag-Pharma Bt. report to view the information.
Registered Capital:
Purchase the Aranyag-Pharma Bt. report to view the information.
Financial Auditors:
Purchase the Aranyag-Pharma Bt. report to view the information.
Incorporation Date:
May 06, 1999
Key Executives
Purchase this report to view the information.
Executive Officer
Ownership Details
Purchase this report to view the information.
Purchase this report to view the information.
Company Performance
Financial values in the chart are available after Aranyag-Pharma Bt. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency HUF. Absolute financial data is included in the purchased report.
Net sales revenue
-14%▼
Total operating revenue
-14.72%▼
Operating profit (EBIT)
-89.22%▼
EBITDA
-85.61%▼
Net Profit (Loss) for the Period
-95.32%▼
Total assets
52.79%▲
Total equity
0.98%▲
Operating Profit Margin (ROS)
-6.03%▼
Net Profit Margin
-5.81%▼
Return on Equity (ROE)
-20.02%▼
Quick Ratio
0.47%▲
Cash Ratio
0.15%▲

To view more information, Request a demonstration of the EMIS service

USD 29.95
Buy this company report
Need ongoing access to company, industry or country information?
Request a demo